Editorials

Interaction of serotonin reuptake inhibitors with tamoxifen

BMJ 2010; 340 doi: http://dx.doi.org/10.1136/bmj.c783 (Published 09 February 2010) Cite this as: BMJ 2010;340:c783
  1. Frank Andersohn, senior research associate,
  2. Stefan N Willich, professor and director
  1. 1Institute for Social Medicine, Epidemiology, and Health Economics, Charité University Medical Centre, 10098 Berlin, Germany
  1. frank.andersohn{at}charite.de

    Avoid coprescribing paroxetine and tamoxifen in women with breast cancer

    Tamoxifen has an established role in the treatment of hormone receptor positive invasive breast cancer.1 Evidence has emerged in recent years that the main pharmacological effects of tamoxifen are not mediated by the parent drug itself but by an active metabolite called endoxifen (4-hydroxy-N-desmethyltamoxifen).2 The bioactivation of tamoxifen to endoxifen is mainly catalysed by the cytochrome P450 isoenzyme 2D6 (CYP2D6).2 Certain drugs inhibit the activity of CYP2D6, and this results in decreased plasma concentrations of endoxifen.2 3

    In the linked observational study (doi:10.1136/bmj.c693), Kelly and colleagues show that the risk of breast cancer related death is higher in women taking tamoxifen plus the selective serotonin reuptake inhibitor (SSRI) paroxetine. The authors suggest that this is explained by inhibition of CYP2D6.4

    SSRIs are prescribed for women with breast cancer who are taking tamoxifen for two main reasons. Firstly, to treat depression or anxiety, and, secondly, to reduce hot flushes, which are a common side effect of tamoxifen. Some SSRIs such as paroxetine are strong inhibitors of CYP2D6. It is reasonable to suggest that concomitant use of these drugs attenuates the clinical effectiveness of tamoxifen, but observational data supporting this hypothesis were lacking until …

    Sign in

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe